Compare ACADIA Pharmaceuticals Inc. (ACAD) vs CleanSpark Inc (CLSK) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
ACADIA Pharmaceuticals Inc. vs CleanSpark Inc — how do they compare? ACADIA Pharmaceuticals Inc. trades at $25.84 (market cap $4.49B), while CleanSpark Inc trades at $12.13 (market cap $3.20B). The key difference: ACADIA Pharmaceuticals Inc. is the larger of the two by market cap, and ACADIA Pharmaceuticals Inc. is trading nearer its 52-week high, CleanSpark Inc nearer its low. Which is the better fit depends on your goals.
| ACAD | CLSK | |
|---|---|---|
Market Cap | $4.49B | $3.20B |
Sector | Health | Technology |
52-Week High | $28.06 | $23.20 |
52-Week Low | $20.06 | $8.18 |
Enterprise Value | $3.69B | $4.06B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ACAD trades at $26.20, up 0.89% today, with strong analyst consensus (70% buy ratings) and a $33.67 price target. Recent CHMP recommendation for Daybue in Europe (Business Wire, June 26, 2026) drove positive sentiment. The stock shows bullish technical signals with moving averages supporting upside, though RSI levels indicate overbought conditions. Fundamentally, revenue grew to $1.07B in 2025 with a robust net income margin of 34.3%, though Q1 2026 earnings missed expectations.
Outlook remains positive given commercial execution and pipeline catalysts like remlifanserin data, but risks include earnings volatility and regulatory dependencies. The stock offers growth potential in neuropsychiatry markets, balanced by execution risks in clinical trials and competitive pressures.
CleanSpark (CLSK) trades at $13.51, up 7.05% today but facing bearish technical signals with recent earnings misses. The company reported strong revenue growth to $766M in 2025 but swung to a net loss margin of -67.66% in 2026. Analyst sentiment remains strongly bullish with 11 buy ratings and a $20.50 consensus target, though cash flow challenges persist with negative operating cash flow of $461M in 2025.
The stock presents a divergence between strong analyst support and challenging fundamentals. While Wall Street sees 100% upside potential, investors face execution risks from profitability challenges and volatile bitcoin mining economics. The technical setup suggests near-term pressure with the stock trading near support levels amid broader market uncertainty.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About ACADIA Pharmaceuticals Inc.
Acadia Pharmaceuticals is a biotechnology company that develops and commercializes biopharmaceutical products to address central nervous system disorders. The company aims to discover small molecule drugs that address disorders such as Parkinson's, Alzheimer's, and schizophrenia. Acadia also seeks to in-license or acquire complementary products and candidates. The company's patent applications claim proprietary technology, including novel methods of screening and chemical synthetic methods, novel drug targets, and novel compounds identified using its technology.
Read more on ACAD →About CleanSpark Inc
CleanSpark is a leading Bitcoin mining company that operates high-density data centers. It focuses on using sustainable energy to power its mining fleet and provides digital infrastructure for the blockchain ecosystem.
Read more on CLSK →
